Allogene Therapeutics Inc

26 de ago. de 2026, 19:56 UTC

Allogene Therapeutics Inc shares are lower during Wednesday's session, continuing a decline since Tuesday amid broader market concerns over persistent inflationary pressures.

25 de ago. de 2026, 23:56 UTC

Allogene Therapeutics Inc. is trading roughly flat in after-market hours, maintaining a position near the upper end of its one-month range.

24 de ago. de 2026, 23:16 UTC

Allogene Therapeutics Inc shares are higher in after-market hours, though this marks the fifth consecutive day of lower closes for the asset.

21 de ago. de 2026, 19:56 UTC

Allogene Therapeutics Inc. shares are lower today, fluctuating within a routine range but remaining above their 20-day moving average.

20 de ago. de 2026, 22:16 UTC

Allogene Therapeutics Inc. shares are higher in after-market hours, despite earlier declines, amid rising U.S. Treasury yields and broader market pressure.

19 de ago. de 2026, 23:01 UTC

Allogene Therapeutics Inc. shares are lower in after-market hours, continuing a decline that began at the start of the session.

18 de ago. de 2026, 19:51 UTC

Allogene Therapeutics Inc. shares are trading lower amid broader market declines and rising Treasury yields, reflecting ongoing pressure in the biotechnology sector.

17 de ago. de 2026, 19:16 UTC

Allogene Therapeutics Inc shares rise following Citizens' Market Outperform rating and $6 price target. The broader Biotechnology sector also shows significant gains.

14 de ago. de 2026, 23:16 UTC

Allogene Therapeutics Inc shares are higher in after-market hours, though no specific news explains the movement. The stock remains above its 20-day moving average.

13 de ago. de 2026, 19:26 UTC

Allogene Therapeutics reported a net loss of $42.7 million, better than expectations, as shares trade lower amid concerns over a potential $500 million offering.

12 de ago. de 2026, 23:21 UTC

Allogene Therapeutics reports narrower net loss of $42.7 million, revenue of $4.64 million. Shares higher after positive trial results and $500 million securities offering announcement.

11 de ago. de 2026, 23:26 UTC

Allogene Therapeutics shares advanced during after-market hours, trading within a narrow range and remaining well above the 20-day moving average.

10 de ago. de 2026, 19:16 UTC

Allogene Therapeutics is trading higher, maintaining upward momentum despite a decline in U.S. stock futures following a labor market report.

7 de ago. de 2026, 19:16 UTC

Biotechnology stocks are rising, boosting Allogene Therapeutics shares. The ARK Genomic Revolution ETF has also increased, reflecting positive sector momentum.

6 de ago. de 2026, 19:46 UTC

Allogene Therapeutics shares are lower, reflecting broader market trends, as the Russell 2000 Index also declined during Thursday's session.

5 de ago. de 2026, 22:01 UTC

Allogene Therapeutics Inc shares are lower in after-market trading, reflecting a pullback from earlier gains amid broader market volatility following weaker U.S. job growth data.

3 de ago. de 2026, 20:06 UTC

Allogene Therapeutics Inc. shares are trading lower, continuing a decline since Friday's close, despite broader market gains in the S&P 500 and Nasdaq 100.

30 de jul. de 2026, 20:04 UTC

Allogene Therapeutics receives RMAT and Fast Track designations from the FDA for cema-cel, contributing to gains in shares today.

29 de jul. de 2026, 23:51 UTC

Allogene Therapeutics receives FDA RMAT and Fast Track designations for cema-cel, boosting shares higher in after-market hours. The Russell 2000 Index's rise may also contribute.

28 de jul. de 2026, 20:02 UTC

Allogene Therapeutics Inc shares are lower amid negative market sentiment following a significant sell-off in technology stocks across Asian markets.

27 de jul. de 2026, 18:07 UTC

Allogene Therapeutics Inc shares are higher today, despite earlier fluctuations. The market backdrop features a decline in oil prices, easing inflation concerns.

24 de jul. de 2026, 19:46 UTC

Allogene Therapeutics Inc is lower today amid broader market declines, with the Russell 2000 Index down and oil price volatility impacting the biotechnology sector.

23 de jul. de 2026, 22:56 UTC

Allogene Therapeutics Inc. shares are roughly flat in after-market trading, remaining below their 20-day moving average and near the lower end of their one-month range.

22 de jul. de 2026, 20:13 UTC

Allogene Therapeutics Inc shares are lower in after-market trading, reflecting broader market declines amid rising crude oil prices and geopolitical tensions.

21 de jul. de 2026, 18:46 UTC

Allogene Therapeutics shares are higher following positive TRAVERSE trial results for ALLO-316, which showed a 25% overall response rate in patients.

20 de jul. de 2026, 23:26 UTC

Allogene Therapeutics Inc. shares are higher in after-market trading, with no specific news identified. Broader market volatility continues to influence investor sentiment.